| Literature DB >> 34328408 |
.
Abstract
Entities:
Year: 2021 PMID: 34328408 PMCID: PMC8662530 DOI: 10.1165/rcmb.v65erratum2
Source DB: PubMed Journal: Am J Respir Cell Mol Biol ISSN: 1044-1549 Impact factor: 6.914
Figure 2.
Consequences of rIL-15 pretreatment in Aspergillus-induced bronchial fibrosis in mice. (A) Representative light-microscopy photomicrographs of lung sections with Masson’s trichrome staining show perivascular and peribronchiolar collagen accumulation after 3 weeks of saline or Aspergillus challenge in mice treated with and without rIL-15. (B) Total collagen expression in saline- and rIL-15–treated, Aspergillus-challenged mice. ELISA results for profibrotic IL-13 and TGF-β1 expression in saline- and rIL-15–treated, Aspergillus-challenged mice are shown. (C and D) Immunofluorescence staining revealed α-SMA+ cells in Aspergillus- and rIL-15–treated, Aspergillus-challenged mice. (E) Very few eosinophils are seen in the saline-treated (for 3 wk) mice. (F) Arrows indicated FSP1+ cell expression in Aspergillus and rIL-15–treated Aspergillus-challenged mice. Quantitation of α-SMA+ and FSP1+ cells is shown in saline-, (G and H) Aspergillus-, and rIL-15–treated Aspergillus-challenged mice. Data are expressed as mean ± SD, n = 12 mice/group. Scale bars: 100 μm and 20 μm. ASP = Aspergillus; FSP1 = fibroblast-specific protein 1; rIL-15 = recombinant IL-15; SAL = saline.
Figure 4.
Pharmacological delivery of IL-15 significantly reduces IL-13–induced collagen accumulation and profibrotic cytokines in the lungs of CC10–IL-13 transgenic mice. (A) Light-microscopy photomicrographs of Masson’s trichome–stained lung sections from saline- or IL-15–treated, no-DOX– or DOX-exposed CC10–IL-13 bitransgenic mice. (B–E) Total lung collagen (B) and the profibrotic cytokines IL-13 (C), TGF-β1 (D), and α-SMA (E) in saline- and IL-15–treated no-DOX– and DOX-exposed IL-13 bitransgenic mice are shown. Data are expressed as mean ± SD, n = 12 mice/group. Scale bars: 100 μm.